SITC 2021 | Asessing the pTVG-HP Plasmid DNA vaccine in patients with mCRPC

Douglas G. McNeel, MD, PhD, University of Wisconsin Carbone Cancer Center, University of Wisconsin, Madison, WI, gives an update of a Phase II trial (NCT02499835) evaluating the pTVG-HP Plasmid DNA Vaccine in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). The trial compared two vaccination schedules. In the first, patients received the vaccine plus pembrolizumab every three weeks. In the second, patients received the vaccine every two weeks and pembrolizumab every four weeks. The second schedule achieved better patient outcomes. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.